Kliniken & Institute ... Kliniken Radiologische Klinik ... Nuklearmedizin Forschung Publikationen

Publikationen

2007

226. Wolf M, Hull WE, Mier W, Heiland S, Bauder-Wust U, Kinscherf R, Haberkorn U, Eisenhut M. Polyamine-Substituted Gadolinium Chelates: A New Class of Intracellular Contrast Agents for Magnetic Resonance Imaging of Tumors. J Med Chem 2007;11;50(1):139-148.

227. Munter MW, Hoffner S, Hof H, Herfarth KK, Haberkorn U, Rudat V, Huber P, Debus J, Karger CP. Changes in salivary gland function after radiotherapy of head-and-neck tumors measured by quantitative pertechnetate scintigraphy: Comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine. Int J Radiat Oncol Biol Phys 2007; 67(3):651-659.

228. Wangler C, Buchmann I, Eisenhut M, Haberkorn, U, Mier W. Radiolabeled peptides and proteins in cancer therapy. Protein Pept Lett 2007;14(3):273-9.

229. Kasper B, Egerer G, Gronkowski M, Haufe S, Lehnert T, Eisenhut M, Mechtersheimer G, Ho AD, Haberkorn U. Functional diagnosis of residual lymph-omas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET. Leukemia and Lymphoma 2007;48(4):746-753.

230. Strauss LG, Klippel S, Pan L, Schönleben K, Haberkorn U, Dimitrakopoulou-Strauss A. Assessment of quantitative PET FDG data in primary colorectal tumours: which parameters are important with respect to the tumour detection? Eur J Nucl Med Mol Imaging 2007; 34:868-877.

231. Hunt A, Schönknecht P, Henze M, Seidl U, Haberkorn U, Schröder J. Reduced cerebral glucose metabolism in patients at risk of developing Alzheimer's disease. Psych Res Neuroim 2007:155(2):147-154.

232. Zitzmann S, Kramer S, Mier W, Hebling U, Altmann A, Rother A, Berndorff D, Eisenhut M, Haberkorn U. Identification and Evaluation of a New Tumor Cell-Binding Peptide, FROP-1. J Nucl Med 2007;.48:965-972.

233. Haberkorn U. Genomics und Proteomics in der Nuklearmedizin. Der Nuklearmedizi-ner 2007;30:11-18.

234. Haberkorn U. Pancreatic cancer – Diagnostics: PET. Chinese German J Clin Oncol 2007;6(2):117-122.

235. Utikal J, Ugurel S, Kurzen H, Erben P, Reiter A, Hochhaus A, Nebe T, Hildenbrand R, Haberkorn U, Goerdt S, Schadendorf D. Imatinib as a Treatment Option for Systemic Non-Langerhans Cell Histiocytosis. Arch Dermatol 2007;143:736-740.

236. Dimitrakopoulou-Strauss A, Hohenberger P, Haberkorn U, Mäcke HR, Eisenhut M, Strauss LG. 68Ga-Labeled Bombesin Studies in Patients with Gastrointestinal Stromal Tumors: Comparison with 18F-FDG. J Nucl Med 2007;48:1245-1250.

237. Frank-Raue K, Fabel M, Delorme S, Haberkorn U, Raue F. Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. Eur J Endocrinol 2007:157(2):215-220.

238. Strauss LG, Pan L, Koczan D, Klippel S, Mikolajczyk K, Burger C, Haberkorn U, Schönleben K, Thiesen HJ, Dimitrakopoulou-Strauss A. Fusion of positron emission tomography (PET) and gene array data: a new approach for the correlative analysis of molecular biological and clinical data. IEEE Trans Med Imaging 2007;26(6):804-812.

239. Mier W, Zitzmann S, Kramer S, Reed J, Knapp EM, Altmann A, Eisenhut M, Ha-berkorn U. Influence of Chelate Conjugation on a Newly Identified Tumor-Targeting Peptide. J Nucl Med 2007;48:1545-1552.

240. Dimitrakopoulou-Strauss A, Hoffmann M, Bergner R, Uppenkamp M, Eisenhut M, Pan L, Haberkorn U, Strauss LG. Prediction of Short-term Survival in Patients with Advanced Nonsmall Cell Lung Cancer Following Chemotherapy Based on 2-Deoxy-2-[F-18]fluoro-D: -glucose-Positron Emission Tomography: A Feasibility Study. Mol Imaging Biol 2007; 9:308-17.

241. Dimitrakopoulou-Strauss A, Hohenberger P, Strobel P, Marx A, Strauss LG. A recent application of fluoro-18-deoxyglucose positron emission tomography, treatment monitoring with a mammalian target of rapamycin inhibitor: an example of a patient with a desmoplastic small round cell tumor. Hell J Nucl Med 2007;10(2):77-9.

242. Graham K, Wang Q, Garcia Boy R, Eisenhut M, Haberkorn U, Mier W. Synthesis and evaluation of intercalating somatostatin receptor binding peptide conjugates for endoradiotherapy. J Pharm Pharm Sci. 2007;10(2):286s-297s.

243. Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schafer M, Schilling T, Haufe S, Herrmann T, Haberkorn U. Comparison of (68)Ga-DOTATOC PET and (111)In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007 May 23; [Epub ahead of print].

244. Hempfing A, Hoffend J, Bitsch RG, Bernd L. The indication for gamma probe-guided surgery of spinal osteoid osteomas. Eur Spine J 2007; [Epub ahead of print].

245. Schabitz WR, Kruger C, Pitzer C, Weber D, Laage R, Gassler N, Aronowski J, Mier W, Kirsch F, Dittgen T, Bach A, Sommer C, Schneider A. A neuroprotective func-tion for the hematopoietic protein granulocyte-macrophage colony stimulating factor (GM-CSF). J Cereb Blood Flow Metab 2007; 1-15 [Epub ahead of print].

246. Schönknecht P, Hunt A, Henze M, Toro P, Seidl U, Pantel J, Haberkorn U, Schröder J. Neural correlates of cognition deficits in mild cognitive impairment and Alzheimer’s disease as assessed by the CERAD neuropsychological test battery. Psych Res Neuroim 2006: in press.

247. Haberkorn U, Hoffend J, Schmidt K, Altmann A, Bonaterra GA, Dimitrakopoulou-Strauss A, Strauss LG, Eisenhut M, Kinscherf R. Metabolic Changes in Rat Hepatomas After Anti-Angiogenic Gene Transfer. Eur J Nucl Med Mol Imaging ; in press.

248. Hunt A, Schönknecht P, Henze M, Toro P, Haberkorn U, Schröder J. CSF tau protein and FDG PET in patients with aging-associated cognitive decline and Alzheimer’s disease. Neuropsychiatric Treament 2006; in press.

249. Barnett W, Henze M, Kröger H, Rotzoll M. New evidence for the etiology of Kleine-Levin syndrome. J Neurol: in review.

250. Mier W, Gabel D, Haberkorn U, Eisenhut M. Peptide-mercaptoundecahydrododecaborate conjugates for the selective boron neutron capture therapy of tumors. Z anorgan allgem Chemie: accepted.

251. Buchmann I, Haberkorn U, Schmidtmann I, Buchholz HG, Kneist W, Bartenstein P, Schreckenberger M, Hansen T. FDG uptake in Squamous Cell Esophageal Carcinoma: Influence of the proliferation rate of tumor cells and content of inflammatory cells. Eur J Nucl Med 2006: submitted.

252. Kontaxakis G, Pozo MA, Ohl R, Visvikis D, Sachpazidis I, Ortega F, Guerra P, Cheze-Le Rest C, Selby P, Pan L, Diaz J, Dimitrakopoulou-Strauss A, Santos A, Strauss LG, Sakas, G. European health telematics networks for positron emission tomography. Nuclear Application for Physics Research 2005, submitted.

253. Kristen AV, Dengler TJ, Helmke B, Hund E, Haberkorn U, Winter P, Katus HA, Altland K. Transthyretin Valine-94-Alanine, a novel variant associated late-onset systemic amyloidosis with cardiac involvement. Human Mutation 2006: submitted.

254. Haberkorn U, Eisenhut M, Altmann A, Mier W. Endoradiotherapy – status and future development. Current Medicinal Chemistry 2007; submitted.

255. Wängler C, Moldenhauer G, Eisenhut M, Haberkorn U, Mier W. Antibody-Dendrimer Conjugates: The Number, Not the Size of the Dendrimers Determines the Immunoreactivity. Bioconjugate Cemistry 2007; submitted.

256. Wängler C, Moldenhauer G, Knapp E, Beijer B, Schnölzer M, Wängler B, Eisenhut M, Haberkorn U, Mier W. Multichromophore PAMAM Dendrimere: Eine Strategie zur Optimierung von Fluoreszenzfarbstoffen für die molekulare Bildgebung. Angew. Chemie International Edition 2007; submitted.

2006

202. Henze M, Özdemir-Sahin N, Hipp P, Mier W, Eisenhut M, Debus J, Haberkorn U. Comparison of the diagnostic accuracy of 18F-FDG PET, 123I-IMT- and 99mTc-MIBI SPECT. Evaluation of tumor progression in irradiated low grade astrocytomas. Nuklearmedizin 2006; 45:49-56.

203. Schmidt K, Hoffend J, Altmann A, Strauss LG, Dimitrakopoulou-Strauss A, Engelhardt B, Koczan D, Peter J, Dengler TJ, Mier W, Eisenhut M, Haberkorn U, Kinscherf R. Angiostatin overexpression in Morris hepatoma results in decreased tumor growth but increased perfusion and vascularization. J Nucl Med 2006;47:543-551.

204. Milker-Zabel S, Zabel-du Bois A, Henze M, Huber P, Schulz-Ertner D, Hoess A, Haberkorn U, Debus J. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [(68)Ga]-DOTATOC-PET. Int J Radiat Oncol Biol Phys 2006;65(1):222-227.

205. Kiessling F, Heilmann M, Lammers T, Ulbrich K, Subr V, Peschke P, Waengler B, Mier W, Schrenk HH, Bock M, Schad L, Semmler W. Synthesis and characterization of HE-24.8: a polymeric contrast agent for magnetic resonance angiography. Bioconjug Chem 2006;17:(1):42-51.

206. Bartenstein M, Baum RP, Dietlein M, Geworski L, Haberkorn U, Kluge R, Knapp WH, Kotzerke J, Kuwert T, Nitzsche E, Reske SN, Reuland P, Schicha H, Schober O, Schwaiger M, Stabell U, van den Hoff, J. Positronen-Emissions-Tomographie in der Onkologie – Bestandteil der ärztlichen Behandlungskunst. Dtsch Med Wo-chenschr 2006;131:512-515.

207. Kontaxakis G, Visvikis D, Ohl R, Sachpazidis, I, Suarez JP, Selby P, Cheze-Le Rest C, Santos A, Ortega F, Diaz J, Pan L, Strauss LG, Dimitrakopoulou-Strauss A, Sakas G, Pozo MA. Integrated telemedicine applications and services for oncological posi-tron emission tomography. Oncol Rep 2006;15(4):1091-100.

208. Haufe SE, Riedmuller K, Haberkorn U. Nuclear medicine procedures for the diagno-sis of acute and chronic renal failure. Nephron Clin Pract 2006;103(2):c77-84.

209. Koukouraki S, Strauss LG, Georgoulias V, Schuhmacher J, Haberkorn U, Karkavitsas N, Dimitrakopoulou-Strauss A. Evaluation of the pharmacokinetic of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006;33:460-466.

210. Dimitrakopoulou-Strauss A, Georgoulias V, Eisenhut M, Herth F, Koukouraki S, Mäcke HR, Haberkorn U, Strauss LG. Quantitative assessment of SSTR2 expression in patients with non-small-cell lung cancer using 68Ga-DOTATOC PET and com-parison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 2006;33:823-830.

211. Chen L, Altmann A, Mier W, Eskerski H, Leotta K, Guo L, Zhu R, Haberkorn U. Radioiodine Therapy of Hepatoma Using Targeted Transfer of the Human So-dium/Iodide Symporter Gene. J Nucl Med 2006;47-854-862.

212. Wolf M, Bauder-Wust U, Pipkorn R, Eskerski H, Eisenhut M. Fluorophor-labeled spermidine derivatives as fluorescent markers in optical tumor imaging. Bioorg Med Chem Lett 2006;16(12):3193-6.

213. Dimitrakopoulou-Strauss A, Strauss LG. Quantitative studies using positron emis-sion tomography (PET) for the diagnosis and therapy planing of oncological pa-tients. Hell J Nucl Med 2006;9(1):10-21.

214. Jensen AD, Munter MW, Bischoff H, Haselmann R, Timke C, Krempien R, Sterzing F, Nill S, Heeger S, Hoess A, Haberkorn U, Huber PE, Steins M, Thomas M, Debus J, Herfarth KK. Treatment of non-small cell lung cancer with intensity-modulated ra-diation therapy in combination with cetuximab: the NEAR protocol (NCT00115518). BMC Cancer 2006:6:122.

215. Askoxylakis V, Mier W, Zitzmann S, Ehemann V, Zhang J, Kramer S, Beck C, Schwab M, Eisenhut M, Haberkorn U. Characterization and Development of a Peptide (p160) with Affinity for Neuroblastoma Cells. J Nucl Med 2006;47(6):981-988.

216. Chen L, Altman A, Mier W, Lu H, Zhu R, Haberkorn U. (99m)Tc-pertechnetate uptake in hepatoma cells due to tissue-specific human sodium iodide symporter gene expression. Nucl Med Biol 2006;33(4):575-580.

217. Calderon Sanchez O, Mohammed A, Bauer C, Wolf M, Wängler B, Mier W, Haberkorn U, Mocelo R, Eisenhut M. 99mTc Complexes with activated ester functions; ligands comprising a 3,4-diamino-benzoate backbone. Nucl Med Biol 2006;33:381-390.

218. Dinter D, Willeke F, Strauss L, Neff KW, Düber C. Staging des Rektumkarzinoms mit CT, MRT und PET. Chir Praxis 2006;66:175-196.

219. Schmidt K, Hoffend J, Altmann A, Kiessling F, Strauss LG, Koczan D, Mier W, Eisenhut M, Kinscherf R, Haberkorn U. Troponin I Overexpression Inhibits Tumor Growth, Perfusion and Vascularization of Morris Hepatoma. J Nucl Med 2006:47:1506-1514.

220. Kunz P, Hoffend J, Altmann A, Strauss LG, Dimitrakopoulou-Strauss A, Koczan D, Eisenhut M, Bonaterra GA, Dengler TJ, Mier W, Haberkorn U, Kinscherf R. Angiopoietin-2-overexpression in Morris hepatoma results in increased tumor perfu-sion and induction of critical angiogenesis-promoting genes. J Nucl Med 2006;47:1515-1524.

221. Dimitrakopoulou-Strauss A, Wilmsmeyer M, König S, Schubert S, Neff KW, Haberkorn U, Strauss LG. 18F-FDG PET in a 10-years-old female patient with subacute sclerosing panencephalitis. Eur J Nucl Med Mol Imaging 2006;33:1100-1101.

222. Eisenhut M, Haberkorn U. Molecular Position of Radiolabels and Its Impact on Functional Integrity of Proteins. J Nucl Med 2006;47 (9):1400-1402.

223. Koukouraki S, Strauss LG, Georgoulias V, Eisenhut M, Haberkorn U, Dimitrakopou-lou-Strauss, A. Comparison of the pharmacokinetics of (68Ga)-DOTATOC and (18F)-FDG in patients with metastatic neuroendocrine tumors scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006; 33:1115-1122.

224. Wolf M, Eskerski H, Bauder-Wust U, Haberkorn U, Eisenhut M. Alkylating benzamides with melanoma cytotoxicity: experimental chemotherapy in a mouse melanoma model. Melanoma Res 2006:16(6):487-96.

225. Buchmann I, Hansen T, Brochhausen C, Kneist W, Oberholzer K, Junginger T, Schreckenberger M , Bartenstein P. FDG-PET in the Inital Staging of Squamous Cell Esophageal Carcinoma. Nuklearmedizin 2006; 45(6):235-41.

2005

175. Gassler N, Zhang C, Wenger T, Schnabel PA, Dienemann H, Debatin KM, Mattern J, Herr I. Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo. Br J Cancer 2005; 28;92(6):1084-8.

176. Maecke HR, Hofmann M, Haberkorn U. Gallium-68 Labeled Peptides in Tumor Imaging. J Nucl Med 2005; 46:172-178.

177. Schwarzbach MH, Hinz U, Dimitrakopoulou-Strauss A, Willeke F, Cardona S, Mechtersheimer G, Lehnert T, Strauss LG, Herfarth C, Buchler MW. Prognostic significance of preoperative (18-F) Fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. Ann Surg 2005; 241(2):286-294.

178. Mier W, Hoffend J, Kramer S, Schuhmacher J, Hull WE, Eisenhut M, Haberkorn U. Conjugation of DOTA using isolated phenolic active esters: labeling and biodistribution of albumin as blood pool marker. Bioconjug Chem 2005;16(1): 237-40.

179. Zitzmann S, Mier W, Schad A, Kinscherf R, Askoxylakis V, Krämer S, Altmann A, Eisenhut M, Haberkorn U. A new prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy. Clin Cancer Res 2005; 11:139-146.

180. Ludwig J, Mechtersheimer G, Haberkorn U, Nawroth P, Schilling T, Kasperk Ch. Oncogenic osteomalacia in a 49-year old female. Dtsch Med Wochenschr 2005;130(5): 206-9.

181. Schmidt K$, Hoffend J$, Altmann A, Strauss LG, Dimitrakopoulou-Strauss A, Engelhardt B, Koczan D, Peter J, Vorwald S, Eskerski H, Eisenhut M, Metz J, Kinscherf R*, Haberkorn U*. Transfer of the sFLT-1 gene in Morris hepatoma results in decreased growth and perfusion and induction of genes associated with stress response. Clin Cancer Res 2005; 11:2132-2140. ($ first authors; *senior authors)

182. Haberkorn U. Einfluss molekularbiologischer Verfahren auf nuklearmedizinische Methoden. Influence of Molecularbiological Techniques upon Nuclearmedical Methods. Der Nuklearmediziner 2005; 28:62-72.

183. Schuhmacher J, Zhang H, Doll J, Mäcke HR, Matys R, Hauser H, Henze M, Haberkorn U, Eisenhut M. GRP Receptor-Targeted PET of a rat pancreas carcinoma xenograft in Nude Mice with a 68Gallium labeled Bombesin (6-14) analog. J Nucl Med 2005;46:691-699.

184. Hoffend J, Mier W, Schuhmacher J, Schmidt K, Dimitrakopoulou-Strauss A, Strauss LG, Eisenhut M, Kinscherf R, Haberkorn U. Gallium-68-DOTA-Albumin as a PET Blood-Pool Marker: Experimental Evaluation in vivo. Nucl Med Biol 2005;32:287-92.

185. Haberkorn U, Mier W, Eisenhut M. Scintigraphic imaging of gene expression and gene transfer. Curr Med Chem 2005;12(7):779-94.

186. Zitzmann S, Krämer S, Mier W, Mahmut M, Fleig J, Altmann A, Eisenhut M, Haberkorn U. Identification of a New Prostate-Specific Cyclic Peptide with the Bac-terial FLiTRx System. J Nucl Med 2005;46:782-785.

187. Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, Maecke HR, Eisenhut M, Debus J, Haberkorn U. Characterization of 68Ga DOTA-D-Phe1-Tyr3-Octreotide Kinetics in Patients with Meningiomas. J Nucl Med 2005;46:763-769.

188. Altmann A, Schulz RB, Glensch G, Eskerski H, Zitzmann S, Eisenhut M, Haberkorn U. Effects of Pax8 and TTF-1 Thyroid Transcription Factor Gene Transfer in Hepatoma Cells: Imaging of Functional Protein-Protein Interaction and Iodide Uptake. J Nucl Med 2005;46(5):831-839.

189. Bauer C, Bauder-Wuest U, Mier W*, Haberkorn U*, Eisenhut M. 131I -Labeled Peptides as Caspases Substrates for Apoptosis Imaging. J Nucl Med 2005;46:1066-1074.

190. Kiessling F, Le-Huu M, Kunert T, Thorn M, Vosseler S, Schmidt K, Hoffend J, Meinzer HP, Fusenig NE, Semmler W. Improved correlation of histological data with DCE MRI parameter maps by 3D reconstruction, reslicing and parameterization of the histological images. Eur Radiol. 2005;15(6):1079-86.

191. Askoxylakis V, Zitzmann S, Mier W, Graham K, Krämer S, von Wegner F, Fink RHA, Schwab M, Eisenhut M, Haberkorn U. Preclinical evaluation of the breast cancer cell binding peptide p160. Clin Cancer Res 2005;11(18):6705-12.

192. Haberkorn U, Eisenhut M. Molecular imaging and therapy-a programme based on the development of new biomolecules. Eur J Nucl Med Mol Imaging 2005;32:1354-1359.

193. Penuelas I, Haberkorn U, Yaghoubi S, Gambhir SS. Gene therapy imaging in patients for oncological applications. Eur J Nucl Med Mol Imaging 2005; 32:384-403.

194. Krause M, Hahnel S, Haberkorn U, Meinck HM. Dopa-responsive hemiparkinsonism due to midbrain Virchow-Robin spaces ? J Neurol 2005; 252:1555-1557.

195. Zhang C, Kolb A, Mattern J, Gassler N, Wenger T, Herzer K, Debatin KM, Buechler M, Friess H, Rittgen W, Edler L, Herr I. Dexamethasone desensitizes hepatocellular and colorectal tumours toward cytotoxic therapy. Cancer Lett 2005;7: [Epub ahead of print].

196. Wolf M, Bauder-Wust U, Haberkorn U, Mier W, Eisenhut M. Alkylating benzamides with melanoma cytotoxicity: role of melanin, tyrosinase, intracellular pH and DNA interaction. Melanoma Res 2005;15(5):383-91.

197. Zitzmann S, Knapp EM, Mier W. Diagnostische Peptide: Spezifische Darstellung und Therapie von Krebserkrankungen. Laborwelt 2005;6:21-23.

198. Schneider A, Kruger C, Steigleder T, Weber D, Pitzer C, Laage R, Aronowski J, Maurer MH, Gassler N, Mier W, Hasselblatt M, Kollmar R, Schwab S, Sommer C, Bach A, Kuhn HG, Schabitz WR. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest 2005;115:2083-2098.

199. Brix G, Schlicker A, Mier W, Peschke P, Bellemann ME. Biodistribution and Pharmacokinetics of the 19F-labeled Radiosensitizer 3-Aminobenzamide: Assessment with 19F MR Imaging. Magn Reson Imaging 2005;23:967-976.

200. Sorg BL, Hull WE, Kliem HC, Mier W, Wiessler M. Synthesis and NMR characterization of hydroxyurea and mesylglycol glycoconjugates as drug candidates for targeted cancer chemotherapy. Carbohydr Res 2005;340:181-189.

201. Thireou T, Kontaxakis G, Strauss LG, Dimitrakopoulou-Strauss A, Pavlopoulos S, Santos A. Feasibility study of the use of similarity maps in the evaluation of oncological dynamic positron emission tomography images. Med Biol Eng Comput. 2005;43(1):23-32.

2004

149. Sieger S, Jiang S, Kleinschmidt J, Eskerski H, Schönsiegel F, Altmann A, Mier W, Haberkorn U. Tumor-specific gene expression using regulatory elements of the glucose transporter isoform 1 gene. Cancer Gene Ther 2004;11:41-51.

150. Wang Q, Graham K, Schauer T, Fietz T, Mohammed A, Liu X, Hoffend J, Haberkorn U, Eisenhut M, Mier W. Pharmacological properties of hydrophilic and lipophilic derivatives of octreotate. Nucl Med Biol 2004;31:21-30.

151. Okouoyo S, Herzer K, Ucur E, Mattern J, Krammer PH, Debatin KM, Herr I: Rescue of death receptor and mitochondrial apoptosis signaling in resistant human NSCLC in vivo. Int J Cancer 2004;108:580-587.

152. Haberkorn U, Altmann A, Mier W, Eisenhut M. Impact of functional genomics and proteomics on radionuclide imaging. Sem Nucl Med 2004;34:4-22.

153. Haberkorn U, Beuter P, Kübler W, Eskerski H, Eisenhut M, Kinscherf R, Zitzmann S, Strauss LG, Dimitrakopoulou-Strauss A, Altmann A. Iodide kinetics and dosimetry in vivo after transfer of the human sodium iodide symporter gene in rat thyroid carcinoma cells. J Nucl Med 2004;45:827-833.

154. Froidevaux S, Calame-Christe M, Schuhmacher J, Tanner H, Saffrich R. Henze M, Eberle AN. A Gallium-labeled DOTA--Melanocyte stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med 2004;45:116-123.

155. Dietz A, Rudat V, Harms W, Jungehülsing M, Dollner R, Henze M. Diagnosis with (18)F-FDG PET scan after larynx preservation by primary radiochemotherapy. HNO 2004;52: 38-44.

156. Henze M, Mohammed A, Schlemmer HP, Herfarth KK, Hoffner S, Haufe S, Mier W, Eisenhut M, Debus J, Haberkorn U. PET and SPECT for detection of tumor progression in irradiated low grade astrocytoma: a receiver-operating-characteristic analysis. J Nucl Med 2004;45:579-586.

157. Henze M, Schuhmacher J, Dimitrakopoulou-Strauss A, Strauss LG, Mäcke HR, Eisenhut M, Haberkorn U. Exceptional increase in somatostatin receptor expression in pancreatic neuroendocrine tumour, visualised with (68)Ga-DOTATOC PET. Eur J Nucl Med Mol Imaging 2004:31: 466.

158. Lichy MP, Bachert P, Henze M, Lichy CM, Debus J, Schlemmer HP. Monitoring individual response to brain-tumour chemotherapy: proton MR spectroscopy in a patient with recurrent glioma after stereotactic radiotherapy. Neuroradiology 2004; 46(2):126-9.

159. Mier W, Graham KAN, Wang Q, Krämer S, Hoffend J, Eisenhut M, Haberkorn U. Synthesis of peptide conjugated chelator oligomers for endoradiotherapy and MRT imaging. Tetrahedron Letters 2004;45:5433-5455.

160. Schoensiegel F, Paschen A, Sieger S, Eskerski H, Mier W, Rothfels H, Kleinschmidt J, Schadendorf D, Haberkorn U. MIA (melanoma inhibitory activity) promoter mediated tissue-specific suicide gene therapy of malignant melanoma. Cancer Gene Therapy 2004;11:408-418.

161. Doll J, Henze M, Bublitz O, Werling A, Adam LE, Haberkorn U, Semmler W, Brix G. High resolution reconstruction of PET images using the iterative OSEM algorithm. Nuklearmedizin 2004;43:72-78.

162. Haberkorn U. Positron emission tomography in the diagnosis of mesothelioma. Lung Cancer 2004;45:73-76.

163. Mier W, Gabel D, Haberkorn U, Eisenhut M. Conjugation of the closo-borane mercaptoundeca-hydrododecaborate (BSH) to a tumour selective peptide. Z anorgan allgem Chemie 2004;630:1258-1262.

164. Strauss LG, Dimitrakopoulou-Strauss A, Koczan D, Bernd L, Haberkorn U, Ewerbeck V, Thiesen HJ. 18F-FDG Kinetics and Gene Expression in Giant Cell Tumors. J Nucl Med 2004;45:1528-1535.

165. Dimitrakopoulou-Strauss A, Strauss LG, Burger C, Ruehl A, Irngartinger G, Stremmel W, Rudi J. Prognostic Aspects of 18F-FDG PET Kinetics in Patients with Metastatic Colorectal Carcinoma Receiving Folfox Chemotherapy. J Nucl Med 2004;45:1480-1487.

166. Korosoglou G, Hansen A, Hoffend J, Gavrilovic G, Wolf D, Zehelein J, Haberkorn U, Kuecherer H. Comparison of real-time myocardial contrast echocardiography for the assessment of myocardial viability with fluorodeoxyglucose-18 positron emission tomography and dobutamine stress echocardiography. Am J Cardiol 2004;94(5):570-576.

167. Wolf M, Bauder-Wüst U, Mohammed A, Schönsiegel F, Mier W, Haberkorn U, Eisenhut M. Alkylating benzamides with melanoma cytotoxicity. Melanoma Res 2004;14:353-360.

168. Thireou T, Kontaxakis G, Strauss LG, Dimitrakopoulou-Strauss A, Pavlopoulos S, Santos A. Feasibility study of the use of similarity maps in the evaluation of on-cological dynamic positron emission tomography images. Med Biol Eng Comput 2004; 42:1-10.

169. Lichy MP, Henze M, Plathow C, Bachert P, Kauczor HU, Schlemmer HP. Metabolische Bildgebung zur Verlaufskontrolle stereotaktisch bestrahlter Gliome – Wertigkeit der 1H-MR-Spektroskopie im Vergleich zur FDG-PET und IMT-SPECT. (Metabolic imaging to follow stereotactic radiation of gliomas -- the role of 1H MR spectroscopy in comparison to FDG-PET and IMT-SPECT). Rofo 2004; 176(8):1114-21.

170. Munter MW, Karger CP, Hoffner SG, Hof H, Thilmann C, Rudat V, Nill S, Wan-nenmacher M, Debus J. Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertech-netate scintigraphy. Int J Radiat Oncol Biol Phys 2004;58(1):175-84.

171. Kim MK, Zitzmann S, Westermann F, Arnold K, Brouwers S, Schwab M, Savelyeva L. Increased rates of spontaneous sister chromatid exchange in lymphocytes of BRCA2+/- carriers of familial breast cancer clusters. Cancer Lett 2004;210(1): 85-94.

172. Mattern J. Cellular drug resistance in lung cancer. Cancer Ther 2004;2:403-414.

173. Efferth T, Koomägi R, Mattern J, Volm M. Lung cancer protein expression profiles of smokers and non-smokers. Cancer Genomics Proteomics 2004;1:249-254.

174. Mattern J, Volm M. Imbalance of cell proliferation and apoptosis during progression of lung carcinomas. Anticancer Research 2004; 24:4243-4246.

2003

121. Wagner S, Eritja R, Zuhayra M, Oberdorfer F, Mohammed A, Mier W, Haberkorn U, Eisenhut M. Synthesis and properties of radiolabeled CPTA-oligonucleotides. J Label Compd Radiopharm 2003;46:175-186.

122. Altmann A, Haberkorn U. Assessment of gene transfer using imaging methodology. Current Genomics 2003;4:167-184.

123. Karger CP, Hipp P, Henze M, Echner G, Höss A, Schad L, Hartmann GH. Stereotactic imaging for radiotherapy: Accuracy of CT, MRI, PET and SPECT. Phys Med Biol 2003;48:211-221.

124. Thireou T, Strauss LG, Dimitrakopoulou-Strauss A, Kontaxakis G, Pavlopoulos S, Santos A. Performance evaluation of principal component analysis in dynamic FDG-PET studies of recurrent colorectal cancer. Computerized Medical Imaging and Graphics 2003;27:43-51.

125. Hoffend J, Linke G, Mohammed A, Tiefenbacher CP, Eisenhut M, Haberkorn U. 99mTcO(BAT-NI), a novel nitroimidazole tracer: in vivo uptake studies in ischaemic myocardium. Eur J Nucl Med Mol Imaging 2003;30:494-501.

126. Kowalski J, Henze M, Schuhmacher J, Mäcke HR, Hofmann M, Haberkorn U. Evaluation of Positron Emission Tomography imaging using 68Ga-DOTA-D Phe1-Tyr3-Octreotide in comparison to 111In-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imag Biol 2003;5:42-48.

127. Haberkorn U, Kinscherf R, Kissel M, Kübler W, Mahmut M, Sieger S, Eisenhut M, Peschke P, Altmann A. Enhanced iodide transport after transfer of the human sodium iodide symporter gene is associated with lack of retention and low absorbed dose. Gene Ther 2003;10:774-780.

128. Sieger S, Jiang S, Schönsiegel F, Eskerski H, Kübler W, Altmann A, Haberkorn U. Tumour-specific activation of the sodium/iodide symporter gene under control of the glucose transporter gene 1 promoter (GTI-1.3). Eur J Nucl Med Mol Imaging 2003;30:748-756.

129. Haberkorn U, Altmann A. Noninvasive imaging of protein-protein interactions in living organisms. Trends Biotechnol 2003;6:241-243.

130. Altmann A, Kissel M, Zitzmann S, Kübler W, Mahmut M, Peschke P, Haberkorn U. Increased MIBG uptake after transfer of the human norepinephrine transporter gene in rat hepatoma. J Nucl Med 2003;44:973-980.

131. Dimitrakopoulou-Strauss A, Strauss LG, Rudi J. PET-FDG as predictor of therapy response in patients with colorectal carcinoma. Q J Nucl Med 2003;47:8-13.

132. Mier W, Eritja R, Mohammed A, Haberkorn U, Eisenhut M. Peptide-PNA Conjugates: Targeted Transport of Antisense Therapeutics into Tumors. Angew Chem Int Ed Engl. 2003;42:1968-1971.

133. Zahn A, Langhans CD, Hoffner S, Haberkorn U, Haass M, Stremmel W, Ruehl A. Measurement of gastric emptying by 13C-octanoic acid breath test versus scintigraphy in diabetics. Validation of the 13C-octanoic acid breath test and relationship to gastric symptoms and cardiovascular autonomic function. Z Gastroenterol 2003;41:383-390.

134. Angelescu M, Kraus T, Wiesel M, Hergesell O, Haberkorn U, Klar E. Assessment of renal graft function by perioperative monitoring of cortical microcirculation in kidney transplantation. Transplantation 2003; 75:1190-1196.

135. Durani BK, Klein A, Henze M, Haberkorn U, Hartschuh W. Somatostatin Analogue Scintigraphy in Merkel Cell Tumours. Brit J Dermatol 2003;148:1135-1140.

136. Haberkorn U, Altmann A. Functional genomics and radioisotope-based imaging procedures. Ann Med 2003;35:370-9.

137. Schönknecht P, Henze M, Hunt A, Klinga K, Haberkorn U, Schröder J. Hippocampal glucose metabolism is associated with cerebrospinal fluid estrogen levels in postmenopausal women with Alzheimer’s disease. Psychiatry Res 2003;124:125-127.

138. Strauss LG, Dimitrakopoulou-Strauss A, Haberkorn U. Shortened PET Data Acquisition Protocol for the Quantification of 18F-FDG Kinetics. J Nucl Med 2003:44; 1933-1939.

139. Mattern J. Drug resistance in cancer: a multifactorial problem. Anticancer Res 2003; 23:1769-1772.

140. Ucur E, Mattern J, Wenger T, Okouoyo S, Schroth A, Debatin KM, Herr I. Induction of apoptosis in experimental human B cell lymphomas by conditional trail-expressing T cells. Br J Cancer 2003; 89:2155-2162.

141. Dimitrakopoulou-Strauss A, Strauss LG. PET imaging of prostate cancer with C-11-acetate (editorial). J Nucl Med 2003;44:556-558.

142. Cardona S, Schwarzbach M, Hinz U, Dimitrakopoulou-Strauss A, Attigah N, Strauss LG, Mechtersheimer G, Lehnert T. Evaluation of F-18-deoxyglucose positron emis-sion tomography (FDG-PET) to assess the dignity of neurogenic tumors. Eur J Surg Onc 2003;29:536-541.

143. Calderon Sanchez O, Mohammed A, Mier W, Graham K, Schuhmacher J, Arndt SO, Haberkorn U, Mocelo R, Eisenhut M. 2,3,5,6-Tetrafluorophenyl N-(S-Benzoylthioacetyl)glycylglycyl- p-aminobenzoate, a Heterobifunctional 99mTc Ligand for Precomplexed Antibody Labeling. Bioconjugate Chemistry 2003;14:1209-1213.

144. Dimitrakopoulou-Strauss A, Strauss LG, Burger C, Mikolajczyk K, Lehnert T, Bernd L, Ewerbeck V. On the fractal nature of dynamic positron emission tomography (PET) studies. W J Nucl Med 2003;2:306-313.

145. Krix M, Kiessling F, Farhan N, Schmidt K, Hoffend J, Delorme S. A multivessel model describing replenishment kinetics of ultrasound contrast agent for quantification of tissue perfusion. Ultrasound Med Biol 2003;29(10):1421-30.

146. Kahle B, Hoffend J, Wacker J, Hartschuh W. Preoperative ultrasonographic identification of the sentinel lymph node in patients with malignant melanoma. Cancer 2003; 97(8):1947-54.

147. Rohrschneider WK, Haufe S, Clorius H, Troger J. MR to assess renal function in children. Eur Radiol 2003;13:1033-45.

148. Dimitrakopoulou-Strauss A, Strauss LG. (eingeladene Arbeit) Fractal dimension based on box-counting: a new parameter for the quantification of dynamic PET stud-ies. Harmonic and Fractal Image Analysis 2003; (HarFA) 42-46.

2002

91. Dimitrakopoulou­Strauss A, Strauss LG, Heichel T, Wu H, Burger C, Bernd L, Ewerbeck V. The role of quantitative (18)F-FDG PET studies for the differentiation of malignant and benign bone lesions. J Nucl Med 2002;43:510-518.

92. Mier W, Haberkorn U, Eisenhut M. [18F]FLT; Portrait of a Proliferation Marker. Eur J Nucl Med 2002;29:165-169.

93. Lichy MP, Henze M, Sammet S, Maudsley AA, Bachert P, Debus J, Schlemmer HP. Clinical decision making in irradiated gliomas: Value of Proton MR Spectroscopy compared to FDG-PET and IMT-SPECT. J Magn Reson Imaging 2002;4:575-576.

94. Schlemmer HP, Lichy MP, Henze M, Sammet S, Maudsley AA, Debus J, Bachert P. Proton MR spectroscopy in irradiated brain tumors. J Magn Reson Imaging 2002;4: 2040-2041.

95. Haberkorn U, Altmann A, Eisenhut M. Functional genomics and proteomics - the role of nuclear medicine. Eur J Nuc Med 2002;29:115-132.

96. Martin SJ, Eisenbarth JA, Wagner-Utermann U, Mier W, Henze M, Pritzkow H, Haberkorn U, Eisenhut M. A New Precursor for the Radiosynthesis of [18F]FLT. Nucl Med Biol 2002;29:263-273.

97. Schlemmer HP, Bachert P, Henze M, Buslei R, Herfarth KK, Debus J, van Kaick G. Differentiation of radiation necrosis from tumor progression using proton magnetic resonance spectroscopy. Neuroradiology 2002;44:216-222.

98. Henze M, Mohammed A, Mier W, Rudat V, Dietz A, Nollert J, Eisenhut M, Haberkorn U. Pretreatment evaluation of carcinomas of the hypopharynx and larynx with F-18-fluorodeoxyglucose, I-123-alpha-methyl-L-tyrosine and Tc-99m-hexakis-2-methoxyisobutylisonitrile. Eur J Nucl Med 2002;29:324-330.

99. Wu H, Dimitrakopoulou-Strauss A, Heichel TO, Lehner B, Bernd L, Ewerbeck V, Burger C, Strauss LG. Quantitative evaluation of skeletal tumors with dynamic Fluorine-18-Fluordeoxyglucose (FDG) PET. Chin J Nucl Med 2002;22:77-80.

100. Kontaxakis G, Strauss LG, Thireou T, Ledesma-Carbayo MJ, Santos A, Pavlopoulos S, Dimitrakopoulou-Strauss A. Iterative image reconstruction for clinical PET using ordered subsets, median root prior, and a web-based interface. Mol Imag Biol 2002;4:219-231.

101. Graham KAN, Wang Q, Eisenhut M, Haberkorn U, Mier W. A general method for functionalising both the C- and N-terminals of Tyr(3)-octreotate. Tetrahedron Letters 2002;43(29):5021-5024.

102. Dimitrakopoulou-Strauss A. The role of Positron Emission Tomography (PET) for diagnosis and therapy monitoring in oncology. Contemporary Medicine 2002;2:16-24.

103. Rohrschneider WK, Haufe S, Möhring K, Wiesel M, Tönshoff B, Clorius JH, Tröger J. Kombinierte statisch-dynamische MR-Urographie zur morphologisch funktionellen Diagnostik angeborener Harntransportstörungen (Combined static-dynamic MR urography for simultaneous morphological and functional diagnosis of congenital urinary tract obstruction). Aktuelle Urologie 2002;33:341-350.

104. Volm M, Koomägi R, Mattern J, Efferth T. Protein expression profile of primary human squamous cell lung carcinomas indicative of the incidence of metastases. Clin Exp Metast 2002;19:385-390.

105. Mattern J, Koomägi R, Volm M. Characteristics of long-term survivors of untreated lung cancer. Lung Cancer 2002;36:277-282.

106. Gutschalk A, Kollmar R, Mohr A, Henze M, Ille N, Schwaninger M, Hartmann M, Hähnel S, Haberkorn U, Rupp A, Meyding-Lamade U. Multimodal functional imaging of prolonged neurological deficits in familial hemiplegic migraine. Neurosci Lett 2002:332:115-118.

107. Efferth T, Koomägi R, Mattern J, Volm M. Expression profile of proteins involved in the xenotransplantability of non-small cell lung cancers into athymic nude mice. Int J Oncol 2002;20:391-395.

108. Volm M, Koomägi R, Mattern J, Efferth T. Protein expression profiles indicative for drug resistance of non-small cell lung cancer. Br J Cancer 2002;87:251-257.

109. Haberkorn U, Altmann A. Radionuclide imaging in the postgenomic era. J Cell Bio-chem 2002;39:1-10.

110. Volm M, Koomägi R, Mattern J, Efferth T. Expression profile of genes in non-small cell lung carcinomas from long-term surviving patients. Clin Cancer Res 2002;8:1843-1848.

111. Clorius JH, Haufe S, Schlotmann A, Haberkorn U. Exercise renography in essential hypertension. Q J Nucl Med 2002; 46(4):311-318.

112. Eisenhut M, Mohammed A, Mier W, Schönsiegel F, Friebe M, Mahmood A, Jones AG, Haberkorn U. Melanoma uptake of Tc-99m complexes containing the N-(2-Diethylaminoethyl)benzamide structural element. J Med Chem 2002; 45:5802-5805.

113. Henze M, Mohammed A, Schlemmer H, Herfarth KK, Mier W, Eisenhut M, Debus J, Haberkorn U. Detection of tumour progression in the follow-up of irradiated low-grade astrocytomas: comparison of 3-[(123)I]iodo-alpha-methyl-L-tyrosine and (99m)Tc-MIBI SPET. Eur J Nucl Med 2002; 29:1455-1461.

114. Volm M, Koomägi R, Efferth T, Mattern J. Protein expression profiles of non-small cell lung carcinomas: correlation with histological subtype. Anticancer Res 2002:22;2321-2324.

115. Mattern J, Koomägi R, Volm M. Expression of drug resistance gene products during progression of lung carcinomas. Oncol Rep 2002;9:1181-1184.

116. Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frölich L, Schönknecht P, Ito K, Mielke R, Kalbe E, Zündorf G, Delbuecke X, Pelati O, Anchisi D, Fazio F, Kerrouche N, Desgranges B, Eustache F, Beuthien-Baumann B, Menzel C, Schröder J, Kato T, Arahata Y, Henze M, Heiss WD. Discrimination between Alzheimer Dementia and Controls by Automated Analysis of Multicenter FDG PET. Neuroimage 2002;17:302-316.

117. Rohrschneider WK, Haufe S, Wiesel M, Tönshoff B, Wunsch R, Darge K, Clorius JH, Tröger J. Functional and morphologic evaluation of congenital urinary tract dila-tation by using combined static-dynamic MR urography: Findings in kidneys with a single collecting system. Radiology 2002;224:683-694.

118. Zitzmann S, Askoxylakis V, Mier W. Phagen-Display Bibliotheken: mit Viren auf der Suche nach neuen Targets. Bioforum 2002;25:490-491.

119. Brix G, Bellemann ME, Ziegler SI, Haberkorn U. Quantification of F-18-FDG uptake in the liver using dynamic PET- Reply. J Nucl Med 2002;43:439-441.

120. Weigand M, Hartung G, Roboz J, Sieger S, Wolf M, Sinn H, Schrenk HH, Wiessler M, Frei E. Mode of action of methotrexate-albumin in a human T-cell leukemia line and activity against an MTX-resistant clone. Anti-Cancer Drug Design 2002;16:227-237.

2001

56. Haberkorn U. Gene therapy with sodium/iodide symporter in hepatocarcinoma. Exp Clin Endocrinol Diabetes 2001;109:60-62.

57. Haberkorn U, Kinscherf R, Krammer PH, Mier W, Eisenhut M. Investigation of a Potential Scintigraphic Marker of Apoptosis: Radioiodinated Z-Val-Ala-DL-Asp(O-Methyl)-fluoromethyl Ketone. Nucl Med Biol 2001;28:793-798.

58. Haberkorn U, Bellemann ME, Brix G, Kamencic H, Morr I, Traut U, Altmann A, Doll J, Blatter J, Kinscherf R. Apoptosis and changes in glucose metabolism after treatment of Morris hepatoma with gemcitabine. Eur J Nucl Med 2001;28:418-425.

59. Haberkorn U, Altmann A, Kamencic H, Morr I, Traut U, Henze M, Jiang S, Metz J, Kinscherf R. Glucose transport and apoptosis after gene therapy with HSV thymidine kinase. Eur J Nucl Med 2001;28:1690-1696.

60. Haberkorn U, Henze M, Altmann A, Jiang S, Morr I, Mahmut M, Peschke P, Kübler W, Debus J, Eisenhut M. Transfer of the human sodium iodine symporter gene enhances iodine uptake in hepatoma cells. J Nucl Med 2001;42:317-325.

61. Haberkorn U, Altmann A, Jiang S, Morr I, Mahmut M, Eisenhut M. Iodide uptake in human anaplastic thyroid carcinoma cells after transfer of the human thyroid peroxidase gene. Eur J Nucl Med 2001;28:633-638.

62. Jiang S, Altmann A, Grimm D, Kleinschmidt JA, Schilling T, Germann C, Haberkorn U. Tissue-specific gene expression in medullary thyroid carcinoma cells employing calcitonin regulatory elements and AAV vectors. Cancer Gene Ther 2001;8:469-472.

63. Brix G, Ziegler SI, Bellemann ME, Doll J, Schosser R, Lucht R, Nosske D, Haberkorn U. Quantification of FDG utilization in the normal liver using dynamic PET: impact and modeling of the dual hepatic blood supply. J Nucl Med 2001;42:1265-1273.

64. Henze M, Schuhmacher J, Hipp P, Kowalski J, Becker D, Doll J, Mäcke H, Hofmann M, Debus J, Haberkorn U. PET imaging of somatostatin receptors using 68Ga-DOTA-D-Phe1-Tyr3-Octreotide (DOTATOC): First results in meningioma patients. J Nucl Med 2001;42:1053-1056.

65. Schlemmer HP, Henze M, Herfarth K, Bachert P, Debus J, van Kaick G. Proton MR spectroscopy and 18F-FDG-PET for the assessment of suspicious lesions after brain tumor radiotherapy. J Magn Reson Imaging 2001;3:2288-2289.

66. Haberkorn U, Schönberg S. Imaging of lung cancer with CT, MRT and PET. Lung Cancer 2001;34/1003:S13-S23.

67. Haberkorn U. PET in der Diagnostik zur Therapieplanung vor Tumoroperationen. Der Chirurg 2001;72:1010-1019.

68. Haberkorn U, Altmann A. Imaging techniques for gene therapy: SPECT, PET and MRI. J Pharmacy Practice 2001;14:383-396.

69. Schuhmacher J, Kaul S, Klivenyi G, Junkermann H, Magener A, Henze M, Doll J, Haberkorn U, Amelung V, Bastert G. Immunoscintigraphy with Positron Emission Tomography: Gallium-68 Chelate Imaging of Breast Cancer Pretargeted with Bispecific Anti-MUC1/Anti-Ga Chelate Antibodies. Cancer Res 2001;61:3712-3717.

70. Haberkorn U, Altmann A. Imaging methods in gene therapy of cancer. Current Gene Ther 2001;1:163-182.

71. Brix G, Henze M, Knopp MV, Lucht R, Doll J, Junkermann H, Hawighorst H, Haberkorn U. Comparison of Pharmacokinetic MR and 18FFluorodeoxyglucose PET in the diagnosis of breast cancer: Initial experience. Eur Radiol 2001;11:2058-2070.

72. Mier W, Eritja R, Mohammed A, Haberkorn U, Eisenhut M. Synthesis and labeling of peptide nucleic acid oligomers conjugated to octreotate. J Labelled Cpd Radio-pharm 2001;44:S954-S956.

73. Mier W, Haberkorn U, Eisenhut M. Synthesis and isolation of active esters of DOTA. J Labelled Cpd Radiopharm 2001;44:S814-S816.

74. Mier W, Rossmann M, Mohammed A, Haberkorn U, Eisenhut M. 3'-end labeling procedure for phosphorothioate oligonucleotides and oligonucleotide-conjugates. J Labelled Cpd Radiopharm 2001;44:S163-S166.

75. Zhou X, Frohlich ED, Clorius JH, Haufe S. Functional and structural involvement of afferent and efferent glomerular arterioles in hypertension. Am J Kidney Dis 2001;37:1092-1097.

76. Brust P, Haubner R, Friedrich A, Scheunemann M, Koufaki ON, Hauses M, Schackert G, Noll S, Noll B, Haberkorn U, Avril N, Schackert HK, Johannsen B. Comparison of [18F]FHPG and [124/125I]FIAU for their potential of monitoring gene therapy. Eur J Nucl Med 2001;28:721-729.

77. Hempel A, Henze M, Berghoff C, Garcia N, Ody R, Schröder J. PET findings and neuropsychological deficits in a case of Fahr`s disease. Psych Res Neuroim 2001;108(2):133-140.

78. Rohrschneider WK, Hoffend J, Becker K, Darge K, Wunsch R, Clorius JH, Kooijman H, Tröger J. Statisch-dynamische MR-Urographie. Vergleich mit Ausscheidungsurographie und Szintigraphie bei experimentell induzierter Harntransportstörung (HTS). Radiologe 2001;41:154-167.

79. Haberkorn U. Positron emission tomography of non small cell lung cancer. Lung Cancer 2001;34/1002:S115-S121.

80. Henze M, Hittel JP. Mucoepidermoid carcinomas of the salivary glands after high-dose radioiodine therapy. Laryngorhinootologie 2001;80:253-256.

81. Schuhmacher J, Klivenyi G, Kaul S, Henze M, Matys R, Hauser H, Clorius J. Pretargeting of human mammary carcinoma xenografts with bispecific anti-MUC1/anti-Ga chelate antibodies and immunoscintigraphy with PET. Nucl Med Biol 2001;28:821-828.

82. Dimitrakopoulou­Strauss A, Strauss LG, Burger C. Quantitative PET­Studies in pretreated melanoma patients: A comparison of 6-(18F)fluoro­L-DOPA with 18F­FDG and 15O­Water using compartment and non­compartment analysis. J Nucl Med 2001;42:248-256.

83. Dimitrakopoulou­Strauss A, Strauss LG, Schwarzbach M, Burger C, Heichel T, Willeke F, Mechtersheimer G, Lehnert T. Dynamic PET­18F-FDG Studies in patients with primary and recurrent soft tissue sarcomas:impact on diagnosis and correlation with grading. J Nucl Med 2001;42:713-720.

84. Schwarzbach M, Dimitrakopoulou­Strauss A, Mechtersheimer G, Hinz U, Willeke F, Cardona S, Attigah N, Strauss LG, Herfarth C, Lehnert T. Assessment of soft tissue lesions suspicious for liposarcoma by F­18­ deoxyglucose (FDG) Positron Emission Tomography (PET). Anticancer Res 2001;21:3609-3614.

85. Wu H, Dimitrakopoulou-Strauss A, Heichel TO, Lehner B, Bernd L, Ewerbeck V, Burger C, Strauss LG. Quantitative evaluation of skeletal tumors with dynamic Fluorine-18-Fluordeoxyglucose (FDG) PET: SUV in comparison to Patlak analysis. Eur J Nucl Med 2001;28:704-710.

86. Strauss LG, Kontaxakis G, Dimitrakopoulou­Strauss A. Performance characteristics of iterative image reconstruction for routine use in Positron Emission Tomography. Alasbimn 2001;3(13). www.alasbimnjournal.cl/revistas/13/strauss.html.

87. Hofmann M, Maecke H, Börner AR, Weckesser E, Schöffski P, Oei ML, Schuma-cher J, Henze M, Heppeler A, Meyer GJ, Knapp WH. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001;28:1751–1757.

88. Delorme S, Haberkorn U, Kinscherf R, Zuna I, Bahner ML, van Kaick G. Changes of tumor vascularity during gene therapy monitored with color Doppler US. Ultra-sound Med Biol 2001;27:1595-1603.

89. Mattern J. Role of angiogenesis in drug resistance. Anticancer Res 2001:21:4265-4270.

90. Mattern J, Volm M. Clinical estimation of the growth rate of lung cancer. Anticancer Res 2001;21:4067-4070.

2000

42. Clorius JH, Schottler T, Haufe S, Zuna I, Reinbold F, Kaick G van. Afferent-efferent vessel dysfunction appears to be a specific characteristic of a large subset of patients with essential hypertension. American Journal of Hypertension 2000;13:332-339.

43. Schwarzbach M, Dimitrakopoulou­Strauss A, Willeke F, Hinz U, Strauss LG, Zhang YM, Mechtersheimer G, Attigah N, Lehnert T, Herfarth C. Clinical value of (18­F) Fluordeoxyglucose Positron Emission Tomography imaging in soft tissue sarcomas. Ann Surg 2000;231(3):380­386.

44. Dimitrakopoulou­Strauss A, Strauss LG, Gutzler F, Rudi J. Parametric PET imaging in patients with hepatocellular carcinomas scheduled for percutaneous ethanol injection: Current and potential applications of C­11­Ethanol. Medical Imaging International 2000;10:6-11.

45. Strauss LG (review). Sensitivity and specificity of positron emission tomography (PET) for the diagnosis of lymph node metastases. Recent Results Cancer Res 2000; 157:12-19.

46. Deigner HP, Haberkorn U, Kinscherf R. Apoptosis modulators in the therapy of neurodegenerative diseases. Exp Opin Invest Drugs 2000; 9:747-764.

47. Brix G, Henze M, Doll J, Lucht R, Zaers J, Trojan H, Knopp MV, Haberkorn U. Diagnostik evaluation of the breast using PET: Optimization of data acquisition and postprocessing. Nuklearmed 2000;39:62-66.

48. Haberkorn U. Neuentwicklungen und Perspektiven der PET. I Apoptose, Peptide, Gentherapie. Der Nuklearmediziner 2000;23:219-229.

49. Eisenhut M, Hull WH, Mohammed A, Mier W, Lay D, Just W, Gorgas K, Lehmann WD, Haberkorn U. Radioiodinated N-(2-Diethylaminoethyl)benzamide Derivatives with High Melanoma Uptake; Structure-Affinity Relationship Studies, Metabolic Fate and Intracellular Localisation J Med Chem 2000;43:3913-3922.

50. Mier W, Eritja R, Mohammed A, Haberkorn U, Eisenhut M. Preparation and Evalua-tion of Tumor-Targeting Peptide-Oligonucleotide Conjugates. Bioconjugate Chemis-try 2000;11:855-860.

51. Wodarski C, Eisenbarth J, Weber K, Henze M, Haberkorn U, Eisenhut M. Synthesis of 3'-deoxy-3'-[18F]fluoro-thymidine with 2,3´-O-anhydro-5´-O-(4,4´-dimethoxytri-tyl) thymidine. J Labeled Compd Radiopharm 2000;43:1211-1218.

52. Eisenhut M, Haberkorn U. (123I)VIP receptor scintigraphy in patients with pancreatic adenocarcinomas. Eur J Nucl Med 2000;27:1589-1590.

53. Rohrschneider WK, Hoffend J, Becker K, Clorius JH, Darge K, Kooijman H, Troeger J. Combined static-dynamic MR urography for the simultaneous evaluation of morphology and function in urinary tract obstruction. I. Evaluation of the normal status in an animal model. Pediatr Radiol 2000;30(8):511-22.

54. Kahle B, Hoffend J, Hartschuh W, Petzoldt D. Ultrasound imaging of the sentinel lymph node in malignant melanoma. Hautarzt 2000;51:915-9.

55. Rohrschneider WK, Becker K, Hoffend J, Clorius JH, Darge K, Kooijman H, Troeger J. Combined static-dynamic MR urography for the simultaneous evaluation of morphology and function in urinary tract obstruction. II. Findings in experimentally induced ureteric stenosis. Pediatr Radiol 2000;30(8):523-32.

1999

28. Brix G, Bellemann ME, Gerlach L, Haberkorn U. Direct detection of intratumoral 5-fluorouracil trapping using metabolic 19F MR imaging. Magn Res Imaging 1999;17:151-155.

29. Brix G, Bellemann ME, Gerlach L, Haberkorn U. Metabolische 19F-MRT und dynamische 18F-PET zum Chemotherapiemonitoring in experimentellen Tumoren. Z Med Phys 1999;9:5-13.

30. Dimitrakopoulou­Strauss A, Strauss LG, Gutzler F, Irngartinger G, Kontaxakis G, Kim DK, Oberdorfer F, van Kaick G. Pharmacokinetic imaging of C­11­Ethanol with PET in eight patients with hepatocellular carcinomas who were scheduled for treatment with percutaneous Ethanol injection. Radiology 1999;211:681­686.

31. Kontaxakis G, Strauss LG, Tzanakos GS. "An efficient implementation of the itera-tive ML-EM image reconstruction algorithm for PET on a Pentium PC platform. J Comp Inf Tech 1999;2:153-163.

32. Schwarzbach M, Willeke F, Dimitrakopoulou­Strauss A, Strauss LG, Zhang YM, Mechtersheimer G, Hinz U, Lehnert T, Herfarth C. Functional imaging and detection of local recurrence in soft tissue sarcomas by Positron Emission Tomography. Anti-cancer Res 1999;19:1343­1350.

33. Kim D, Strauss LG, Dimitrakopoulou­Strauss A, Gutzler F, Irngartinger G, Kontaxakis G. The sequential FDG­PET study of percutaneous Ethanol injection treated hepatoma patients. Dong­A Clinical Research 1999;1:25­30.

34. Mantaka P, Dimitrakopoulou­Strauss A, Strauss LG, Moehler M, Goldschmidt H, Oberdorfer F, Kontaxakis G, van Kaick G. Detection of treated liver metastases using Fluorine­ 18­Fluordeoxyglucose (FDG) and Positron Emission Tomography (PET). Anticancer Res 1999;19:4443­4450.

35. Dimitrakopoulou­Strauss A. Applications of PET in clinical oncology. Greek Journal of Nuclear Medicine 1999;2:134­144.

36. Benck U, Clorius JH, Zuna I, Ritz E. Renal hemodynamic changes during smoking: effects of adrenoreceptor blockade. European Journal of Clinical Investigation 1999;29:1010-1018.

37. Kissel J, Port RE, Zaers J, Bellemann ME, Strauss LG, Haberkorn U, Brix G. Noninvasive determination of the arterial input function of an anticancer drug from dynamic PET scans using the population approach. Med Phys 1999;26:609-615.

38. Haberkorn U. Monitoring of gene transfer for cancer therapy with radioactive isotopes. Ann Nucl Med 1999;13:369-377.

39. Brix G, Bellemann ME, Haberkorn U. Biochemical modulation of the catabolism and tissue uptake of the anticancer drug 5-fluorouracil by 5-bromovinyluracil: assessment with metabolic 19F MR imaging. Magnetic Res Med 1999;42:936-943.

40. Haufe S, Clorius JH. Nuklearmedizinische Nierendiagnostik. Radiologe 1999;39: 386-397.

41. Haberkorn U. Gentherapie mit Selbstmordgenen. Ruperts Carola-Forschungsmagazin der Universität Heidelberg. 1999;3:22-27.

1998

20. Bepler U, Dimitrakopoulou­Strauss A, Kontaxakis G, Strauss LG. Functional studies of F­18­Deoxyglucose (FDG) in small cell lung tumours using Positron Emission Tomography (PET). Greek Journal of Nuclear Medicine 1998;1:231­239.

21. Haberkorn U, Khazaie K, Morr I, Altmann A, Müller M, Kaick G. van. Ganciclovir uptake in human mammary carcinoma cells expressing Herpes Simplex Virus thymidine kinase. Nucl Med Biol 1998;25:367-373.

22. Henze M, Hittel JP, Elser H. Mucoepidermoid carcinoma of the submandibular gland after high-dose radiation therapy: case report and review of the literature. Nuklear-medizin 1998;37:38-42.

23. Haberkorn U, Bachert P, Gerlach L, Morr I, Wiessler M, Kaick G. van. Assessment of glucosylifosfamide biodistribution in rats with prostate adenocarcinomas by means of in vivo 31P NMR and in vitro uptake experiments. Magnetic Reson Med 1998;39:754-761.

24. Haberkorn U, Bellemann ME, Gerlach L, Morr I, Trojan H, Brix G, Altmann A, Doll J, Kaick G van. Uncoupling of 2-fluoro-2-deoxyglucose transport and phosphorylation in rat hepatoma during gene therapy with HSV thymidine kinase. Gene Ther 1998;5:880-887.

25. Germann C, Shields AF, Grierson JR, Morr I, Haberkorn U. 5-Fluoro-1-(2´-deoxy-2´-fluoro-ß-D-ribofuranosyl)uracil trapping in Morris hepatoma cells expressing the Herpes Simplex Virus thymidine kinase gene. J Nucl Med 1998;39:1418-1423.

26. Brix G, Bellemann ME, Gerlach L, Haberkorn U. Intra- and extracellular 5-Fluoruracil uptake in rats with Morris hepatoma as detected with contrast-enhanced metabolic 19F MR imaging. Radiology 1998;209:259-267.

27. Doll J, Zaers J, Trojan H, Bellemann ME, Adam LE, Haberkorn U, Brix G. Optimie-rung der Bildqualität von PET-Aufnahmen durch 3D-Datenaquisition und iterative Bildrekonstruktion. Nuklearmedizin 1998;37:62-67.

1997

1. Dimitrakopoulou­Strauss A, Strauss LG, Goldschmidt G, Hegenbart U, Irngartinger G, Oberdorfer F, van Kaick, G. Die Positronenemissionstomographie (PET) bei der Diagnostik und Therapieplanung von malignen Lymphomen. Radiologe 1997;37:74­80.

2. Kuhn GD, Reißer C, Dimitrakopoulou­Strauss A, Oberdorfer F, Strauss LG. PET studies of perfusion and glucose metabolism in patients with untreated head and neck tumors. Onkologie 1997;20:226­23.

3. Haberkorn U, Altmann A, Morr I, Knopf KW, Germann C, Haeckel R, Oberdorfer F, Kaick G van. Gene therapy with Herpes Simplex Virus thymidine kinase in hepatoma cells: uptake of specific substrates. J Nucl Med 1997;38:287-294.

4. Elser H, Henze M, Hermann C, Eckert W, Mende U. 99mTc-MIBI for recurrent and metastatic differentiated thyroid carcinoma. Nuklearmed 1997;36:7-12.

5. Clorius JH, Hupp T, Zuna I, Schmidlin P, Denk S, Kaick G van. The exercise renogram and its interpretation. J Nucl Med 1997;38:1146-1151.

6. Haberkorn U, Altmann A, Morr I, Germann C, Oberdorfer F, Kaick G van. Multi tracer studies during gene therapy of hepatoma cells with HSV thymidine kinase and ganciclovir. J Nucl Med 1997;38:1048-1054.

7. Haberkorn U, Bellemann ME, Altmann A, Gerlach L, Morr I, Oberdorfer F, Brix G, Doll J, Blatter J, Kaick G van. F-18-fluoro-2-deoxyglucose uptake in rat prostate adenocarcinoma during chemotherapy with 2',2'-difluoro-2'-deoxycytidine. J Nucl Med 1997;38:1215-1221.

8. Brix G, Zaers J, Adam LE, Bellemann ME, Ostertag H, Trojan H, Haberkorn U, Doll J, Lorenz WJ. Performance evaluation of the whole-body PET scanner ECAT EXACT HR+ according to the NEMA protocol. J Nucl Med 1997;38:1614-1623.

9. Haberkorn U, Bellemann ME. Positronenemissionstomographie. Med Monatsschrift für Pharmazeuten 1997;20:117-125.

10. Brix G, Doll J, Bellemann ME, Trojan H, Haberkorn U, Schmidlin P, Ostertag H. Use of scanner characteristics in iterative image reconstruction for high-resolution PET studies of small animals. Eur J Nucl Med 1997;24:779-786.

11. Kissel J, Brix G, Bellemann ME, Strauss LG, Dimitrakopoulou-Strauss A, Port R, Haberkorn U, Lorenz WJ. Pharmacokinetic analysis of 5-(18F)fluorouracil tissue concentrations measured by positron emission tomography (PET) in patients with liver metastases from colorectal adenocarcinoma. Cancer Res 1997;57:3415-3423.

12. Strauss LG. Positron Emission Tomography: Current Role for Diagnosis and Therapy Monitoring in Oncology. Oncologist 1997;2(6):381-38.

13. Yu CS, Eisenbarth J, Weber K, Haberkorn U, Zeisler SK, Oberdorfer F. Synthesis of 5-(2-radiohaloethyl)-2‘-deoxyuridines. Useful tools for virus thymidine kinase transfected tumor cells. J Labelled Compounds and Radiopharmaceuticals 1997;39:402.

14. Schuknecht B, Daecke W, Bernd L, Lange D, Hoffend J. Erfahrungen mit der intraoperativen Lokalisation von Osteoid-Osteomen mit einem Szintillationsdetektor. Akt Traumatol 1998;28:105-109.

15. Eisenhut M, Lehmann WD, Hull WE, Just WW, Hoffend J, Zehelein J, Zimmermann R. Trapping and metabolism of radioiodinated PHIPA 3-10 in the rat myocardium. J Nucl Med 1997;38:1864-9.

16. Dimitrakopoulou­Strauss A, Strauss LG, Schlag P, Hohenberger P, Irngartinger G, Oberdorfer F, Doll J, van Kaick G. Intravenous and intra­arterial Oxygen­15­Labeled Water and Fluorine­18­Labeled Fluorouracil in patients with liver metastases from colorectal carcinoma. J Nucl Med 1998;39:465­473.

17. Möhler M, Dimitrakopoulou­Strauss A, Gutzler F, Räth U, Strauss LG, Stremmel W. 18F­Labeled Fluorouracil Positron Emission Tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5­Fluorouracil. Cancer 1998;83:245­253.

18. Dimitrakopoulou­Strauss A, Strauss LG, Schlag P, Hohenberger P, Möhler M, Ober-dorfer F, van Kaick G. Fluorine­18­Fluorouracil to predict therapy response in liver metastases from colorectal carcinoma. J Nucl Med 1998;39:1197­1202.

19. Dimitrakopoulou G, Dimitrakopoulou­Strauss A, Stathopoulou A, Alexopoulou, Artinopoulos C, Oberdorfer F, Strauss LG. PET studies with F­18­Fluorouracil and O­15­labeled Water in patients with liver metastases from colorectal carcinoma: A comparison between intraarterial and systemic application. Greek Journal of Nuclear Medicine 1998;1:171­176.